Thursday, January 29, 2015 9:22:30 AM
In October 2013 we had to cease trialing the process due to lack of available and sustainable funds.The new initiative to generate investment into the company will allow us to recommence these trials and move towards selling the equine product on the open market. As a result, the Company is still in development and approval stage.
We are looking to raise the estimated $2 million required to obtain US Food and Drug Administration approval of the
patented process for humans and to make the product available to our targeted markets. This process has continued
and has found some success following the release into the market of converted stocks. Interest in our shares has
continued with the conversion of further amounts of our long-term debt into Common Stock which has in turn
necessitated our increasing the authorized capital of the Company. Further increases are not deemed necessary at
present. Although we are still short of our targetted investment level which would allow trials to recommence, we have
been developing other long-term investment possibilities which will not come to fruition until the first quarter of 2015.
Please note that the $2 million figure has not changed for years. A smart company would tell it's investors they still need $X to reach their goal of $2 million to restart the trialing to prepare for FDA submission!.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM